Prosecution Insights
Last updated: November 04, 2026
Application No. 18/699,868

FLUORESCENT BARCODING OF MICROPARTICLES

Non-Final OA §103
Filed
Apr 09, 2024
Priority
Oct 10, 2021 — provisional 63/254,161 +1 more
Examiner
LAFAVE, ELIZABETH ROSE
Art Unit
Tech Center
Assignee
Celldom Inc.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
1y 8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
40 granted / 61 resolved
+5.6% vs TC avg
Strong +44% interview lift
Without
With
+43.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
25 currently pending
Career history
99
Total Applications
across all art units

Statute-Specific Performance

§101
9.5%
-30.5% vs TC avg
§103
31.4%
-8.6% vs TC avg
§102
28.7%
-11.3% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 61 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Applicant amended claims 1, 3-6, 8, 12-13, 16-18 (4/9/2024) and cancelled claims 20-63 (4/9/2024). No new matter was added. Thus, claims 1-19 are under examination. Priority Claims 1-19 receive a priority date of 10/10/2021, the filing date of US Provisional No. 63254161. Information Disclosure Statement The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. No Information Disclosure Statements were submitted, and therefore none were considered. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-19 are rejected are rejected under 35 U.S.C. 103 as being unpatentable over Fan et al. (US PGPub 2018/0088112 A1; published 3/29/2018). Regarding claims 1-8, Fan teaches that some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide, where the oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target, and further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample, and also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide (Abstract). Further, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof. In some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 202, lines 1-5). Fan also teaches that the label is conjugated to the biomolecule through a linker, where the label can comprise the linker and the linker can comprise a chemical group and the chemical group can be reversibly attached to the biomolecule where the chemical group can be selected from the group consisting of a UV photocleavable group, a streptavidin, a biotin, an amine, and any combination thereof (Paragraph 207, lines 1-3). Fan also teaches that the unique identifier may not be homologous to genomic sequences of a sample, where the sample can be a single cell, a plurality of cells, a tissue, a tumor sample, or any combination thereof (the sample can be a mammalian sample, a bacterial sample, a viral sample, a yeast sample, a fungal sample, or any combination thereof), and the oligonucleotide can comprise a barcode sequence (e.g., a molecular label sequence), a poly(A) tail, or a combination thereof (Paragraph 208, lines 1-5). Specifically, Fan teaches that in some embodiment, the biomolecule comprises a polypeptide, a nucleic acid, a polysaccharide, or any combination thereof, where the nucleic acid can be an oligonucleotide, DNA or RNA and the polypeptide can be a protein, an enzyme or a protein binding reagent, where the protein binding reagent can comprise an antibody, an aptamer, or a combination thereof and the protein binding reagent conjugated with the label can be capable of specifically binding to at least one of a plurality of protein targets (Paragraph 210, lines 1-5). Also, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof and in some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 212, lines 1-5). Fan further teaches that in some embodiments, the oligonucleotide comprises a unique identifier for the biomolecule, where the unique identifier can comprise a nucleotide sequence of 25-45 nucleotides in length and the unique identifier can be selected from a diverse set of unique identifiers and the diverse set of unique identifiers can comprise at least 100, 1,000, or 10,000 different unique identifiers and where the oligonucleotide can have a sequence selected from at least 10, 100, or 1,000 different barcode sequences (Paragraph 216, lines 1-5). Regarding claims 9-13, Fan teaches that some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide, where the oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target, and further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample, and also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide (Abstract). Fan teaches that in some embodiments, the method comprises contacting the cell with a second pair of interaction determination compositions, wherein the cell comprises a third protein target and a fourth protein target, wherein each of the second pair of interaction determination compositions comprises a protein binding reagent associated with an interaction determination oligonucleotide, wherein the protein binding reagent of one of the second pair of interaction determination compositions is capable of specifically binding to the third protein target and the protein binding reagent of the other of the second pair of interaction determination compositions is capable of specifically binding to the fourth protein target and at least one of the third and fourth protein targets can be different from one of the first and second protein targets and at least one of the third and fourth protein targets and at least one of the first and second protein targets can be identical (Paragraph 163, lines 1-10). Further, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof. In some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 202, lines 1-5). Fan also teaches that the label is conjugated to the biomolecule through a linker, where the label can comprise the linker and the linker can comprise a chemical group and the chemical group can be reversibly attached to the biomolecule where the chemical group can be selected from the group consisting of a UV photocleavable group, a streptavidin, a biotin, an amine, and any combination thereof (Paragraph 207, lines 1-3). Fan also teaches that the unique identifier may not be homologous to genomic sequences of a sample, where the sample can be a single cell, a plurality of cells, a tissue, a tumor sample, or any combination thereof (the sample can be a mammalian sample, a bacterial sample, a viral sample, a yeast sample, a fungal sample, or any combination thereof), and the oligonucleotide can comprise a barcode sequence (e.g., a molecular label sequence), a poly(A) tail, or a combination thereof (Paragraph 208, lines 1-5). Specifically, Fan teaches that in some embodiment, the biomolecule comprises a polypeptide, a nucleic acid, a polysaccharide, or any combination thereof, where the nucleic acid can be an oligonucleotide, DNA or RNA and the polypeptide can be a protein, an enzyme or a protein binding reagent, where the protein binding reagent can comprise an antibody, an aptamer, or a combination thereof and the protein binding reagent conjugated with the label can be capable of specifically binding to at least one of a plurality of protein targets (Paragraph 210, lines 1-5). Also, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof and in some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 212, lines 1-5). Fan further teaches that in some embodiments, the oligonucleotide comprises a unique identifier for the biomolecule, where the unique identifier can comprise a nucleotide sequence of 25-45 nucleotides in length and the unique identifier can be selected from a diverse set of unique identifiers and the diverse set of unique identifiers can comprise at least 100, 1,000, or 10,000 different unique identifiers and where the oligonucleotide can have a sequence selected from at least 10, 100, or 1,000 different barcode sequences (Paragraph 216, lines 1-5). Fan teaches that a barcode can comprise one or more spatial labels, and in some embodiments, a spatial label can comprise a nucleic acid sequence that provides information about the spatial orientation of a target molecule which is associated with the barcode, where a spatial label can be associated with a coordinate in a sample, where the coordinate can be a fixed coordinate and for example a coordinate can be fixed in reference to a substrate (Paragraph 317, lines 1-5). Further, Fan teaches that a spatial label can be in reference to a two or three-dimensional grid and a coordinate can be fixed in reference to a landmark, where the landmark can be identifiable in space and a landmark can be a structure which can be imaged, where a landmark can be a biological structure, for example an anatomical landmark, where a landmark can be a cellular landmark, for instance an organelle, where a landmark can be a non-natural landmark such as a structure with an identifiable identifier such as a color code, bar code, magnetic property, fluorescents, radioactivity, or a unique size or shape, where a spatial label can be associated with a physical partition (e.g. a well, a container, or a droplet) and in some embodiments, multiple spatial labels are used together to encode one or more positions in space (Paragraph 317, lines 1-15). Fan also teaches that following lysis of the cells and release of nucleic acid molecules therefrom, the nucleic acid molecules can randomly associate with the barcodes of the co-localized solid support and association can comprise hybridization of a barcode's target recognition region to a complementary portion of the target nucleic acid molecule (e.g., oligo(dT) of the barcode can interact with a poly(A) tail of a target), where the assay conditions used for hybridization (e.g. buffer pH, ionic strength, temperature, etc.) can be chosen to promote formation of specific, stable hybrids and in some embodiments, the nucleic acid molecules released from the lysed cells can associate with the plurality of probes on the substrate (e.g., hybridize with the probes on the substrate) (Paragraph 424, lines 1-5). Further, Fan teaches that when the probes comprise oligo(dT), mRNA molecules can hybridize to the probes and be reverse transcribed, and the oligo(dT) portion of the oligonucleotide can act as a primer for first strand synthesis of the cDNA molecule and for example, in a non-limiting example of barcoding illustrated in FIG. 2, at block 216, mRNA molecules can hybridize to barcodes on beads and for example, single-stranded nucleotide fragments can hybridize to the target-binding regions of barcodes (Paragraph 424, lines 5-15). Regarding claims 14-19, Fan teaches that some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide, where the oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target, and further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample, and also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide (Abstract). Fan teaches that in some embodiments, the method comprises contacting the cell with a second pair of interaction determination compositions, wherein the cell comprises a third protein target and a fourth protein target, wherein each of the second pair of interaction determination compositions comprises a protein binding reagent associated with an interaction determination oligonucleotide, wherein the protein binding reagent of one of the second pair of interaction determination compositions is capable of specifically binding to the third protein target and the protein binding reagent of the other of the second pair of interaction determination compositions is capable of specifically binding to the fourth protein target and at least one of the third and fourth protein targets can be different from one of the first and second protein targets and at least one of the third and fourth protein targets and at least one of the first and second protein targets can be identical (Paragraph 163, lines 1-10). Further, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof. In some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 202, lines 1-5). Fan also teaches that the label is conjugated to the biomolecule through a linker, where the label can comprise the linker and the linker can comprise a chemical group and the chemical group can be reversibly attached to the biomolecule where the chemical group can be selected from the group consisting of a UV photocleavable group, a streptavidin, a biotin, an amine, and any combination thereof (Paragraph 207, lines 1-3). Fan also teaches that the unique identifier may not be homologous to genomic sequences of a sample, where the sample can be a single cell, a plurality of cells, a tissue, a tumor sample, or any combination thereof (the sample can be a mammalian sample, a bacterial sample, a viral sample, a yeast sample, a fungal sample, or any combination thereof), and the oligonucleotide can comprise a barcode sequence (e.g., a molecular label sequence), a poly(A) tail, or a combination thereof (Paragraph 208, lines 1-5). Specifically, Fan teaches that in some embodiment, the biomolecule comprises a polypeptide, a nucleic acid, a polysaccharide, or any combination thereof, where the nucleic acid can be an oligonucleotide, DNA or RNA and the polypeptide can be a protein, an enzyme or a protein binding reagent, where the protein binding reagent can comprise an antibody, an aptamer, or a combination thereof and the protein binding reagent conjugated with the label can be capable of specifically binding to at least one of a plurality of protein targets (Paragraph 210, lines 1-5). Also, Fan teaches that in some embodiments, the label comprises a fluorophore, a chromophore, a polypeptide, a protein, an enzyme, an enzyme substrate, a catalyst, a redox label, a radiolabels, an acoustic label, a Raman (SERS) tag, a mass tag, an isotope tag, a magnetic particle, a microparticle, a nanoparticle, an oligonucleotide, or any combination thereof and in some embodiments, the label comprises an enzyme, an enzyme substrate, or a combination thereof, and wherein the enzyme is capable of modifying the enzyme substrate into a corresponding modified enzyme substrate (Paragraph 212, lines 1-5). Fan further teaches that in some embodiments, the oligonucleotide comprises a unique identifier for the biomolecule, where the unique identifier can comprise a nucleotide sequence of 25-45 nucleotides in length and the unique identifier can be selected from a diverse set of unique identifiers and the diverse set of unique identifiers can comprise at least 100, 1,000, or 10,000 different unique identifiers and where the oligonucleotide can have a sequence selected from at least 10, 100, or 1,000 different barcode sequences (Paragraph 216, lines 1-5). Fan teaches that a barcode can comprise one or more spatial labels, and in some embodiments, a spatial label can comprise a nucleic acid sequence that provides information about the spatial orientation of a target molecule which is associated with the barcode, where a spatial label can be associated with a coordinate in a sample, where the coordinate can be a fixed coordinate and for example a coordinate can be fixed in reference to a substrate (Paragraph 317, lines 1-5). Further, Fan teaches that a spatial label can be in reference to a two or three-dimensional grid and a coordinate can be fixed in reference to a landmark, where the landmark can be identifiable in space and a landmark can be a structure which can be imaged, where a landmark can be a biological structure, for example an anatomical landmark, where a landmark can be a cellular landmark, for instance an organelle, where a landmark can be a non-natural landmark such as a structure with an identifiable identifier such as a color code, bar code, magnetic property, fluorescents, radioactivity, or a unique size or shape, where a spatial label can be associated with a physical partition (e.g. a well, a container, or a droplet) and in some embodiments, multiple spatial labels are used together to encode one or more positions in space (Paragraph 317, lines 1-15). Fan also teaches that following lysis of the cells and release of nucleic acid molecules therefrom, the nucleic acid molecules can randomly associate with the barcodes of the co-localized solid support and association can comprise hybridization of a barcode's target recognition region to a complementary portion of the target nucleic acid molecule (e.g., oligo(dT) of the barcode can interact with a poly(A) tail of a target), where the assay conditions used for hybridization (e.g. buffer pH, ionic strength, temperature, etc.) can be chosen to promote formation of specific, stable hybrids and in some embodiments, the nucleic acid molecules released from the lysed cells can associate with the plurality of probes on the substrate (e.g., hybridize with the probes on the substrate) (Paragraph 424, lines 1-5). Further, Fan teaches that when the probes comprise oligo(dT), mRNA molecules can hybridize to the probes and be reverse transcribed, and the oligo(dT) portion of the oligonucleotide can act as a primer for first strand synthesis of the cDNA molecule and for example, in a non-limiting example of barcoding illustrated in FIG. 2, at block 216, mRNA molecules can hybridize to barcodes on beads and for example, single-stranded nucleotide fragments can hybridize to the target-binding regions of barcodes (Paragraph 424, lines 5-15). Fan also teaches that this disclosure provides for a method to create a target-barcode conjugate using reverse transcription (e.g., at block 224 of FIG. 2), where the target-barcode conjugate can comprise the barcode and a complementary sequence of all or a portion of the target nucleic acid (i.e. a barcoded cDNA molecule, such as a stochastically barcoded cDNA molecule) and reverse transcription of the associated RNA molecule can occur by the addition of a reverse transcription primer along with the reverse transcriptase, where the reverse transcription primer can be an oligo(dT) primer, a random hexanucleotide primer, or a target-specific oligonucleotide primer. Oligo(dT) primers can be, or can be about, 12-18 nucleotides in length and bind to the endogenous poly(A) tail at the 3′ end of mammalian mRNA and target-specific oligonucleotide primers typically selectively prime the mRNA of interest (Paragraph 429, lines 1-10). Specifically, Fan teaches that reverse transcription can occur repeatedly to produce multiple labeled-cDNA molecules and the methods disclosed herein can comprise conducting at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 reverse transcription reactions and the method can comprise conducting at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 reverse transcription reactions (Paragraph 431, lines 1-5). Fan further teaches that one or more nucleic acid amplification reactions (e.g., at block 228 of FIG. 2) can be performed to create multiple copies of the labeled target nucleic acid molecules and amplification can be performed in a multiplexed manner, wherein multiple target nucleic acid sequences are amplified simultaneously and the amplification reaction can be used to add sequencing adaptors to the nucleic acid molecules, where amplification reactions can comprise amplifying at least a portion of a sample label, if present and the amplification reactions can comprise amplifying at least a portion of the cell label and/or barcode sequence (e.g., molecular label) (Paragraph 433, lines 1-10). It would have been obvious to one of ordinary skill in the art before the effective filing date to modify the methods taught by Fan to provide microparticles having one or more fluorophores linked thereto by one or more cleavable linkers, including different fluorophores and/or cleavable linkers, and to use the resulting combinations as fluorescent identifying barcodes. Fan expressly teaches the use of fluorophores, microparticles, oligonucleotide barcodes and other identifying labels, as well as reversible linkers including UV-photocleavable groups. Fan further teaches the use of multiple and diverse unique identifiers and the use of multiple labels together for encoding purposes. Thus, the proposed modification represents the combination of known labeling and encoding components disclosed by Fan according to their established functions to provide distinguishable, multiplexed identifiers. One of ordinary skill in the art would have been motivated to make such a modification because employing different combinations of fluorophores and selectively cleavable linkers would predictably increase the number of distinguishable encoding states obtainable from the particles and permit the encoded particles to be differentiated and/or decoded in a multiplexed assay. The modification would therefore further Fan’s expressly disclosed objective of uniquely identifying and distinguishing different biomolecules, targets, and/or spatially associated particles using diverse identifiers and labels. Regarding claim 14’s workflow, specifically, it would have been obvious to employ Fan’s cleavable fluorophore labeling system in the claimed cleave, detect, correlate, and identify workflow. Fan teaches fluorphore labels, reversible/photocleavable linkers, and barcodes or unique identifiers. A skilled artisan would have been motivated to cleave and detect the fluorphore and correlate the resulting signal with its associated barcode because this predictably uses each component for its disclosed function to identify the encoded microparticle. For embodiments involving repeated detection or different cleaving agents, repeating the cleavage and detection using distinguishable fluorophores and/or independently cleavable linkers would have been an obvious extension of Fan’s teachings of multiple labels, diverse identifiers, multiplexing, and reversible attachment, thereby permitting additional encoding information to be obtained. A skilled artisan would have had a reasonable expectation of success because Fan teaches the underlying components and techniques—microparticles, fluorophores, barcode identifiers, cleavable linkers, and multiplexed detection. The modification would not alter their established functions and would predictably permit identification of an encoded microparticle through controlled release and detection of its fluorescent label. See MPEP 2143 and 2143.02. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELIZABETH ROSE LAFAVE whose telephone number is (703)756-4747. The examiner can normally be reached Compressed Bi-Week: M-F 7:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached on 571-272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ELIZABETH ROSE LAFAVE/Examiner, Art Unit 1684 /HEATHER CALAMITA/Supervisory Patent Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Apr 09, 2024
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781266
SYNTHETIC POLYNUCLEOTIDES AND METHOD OF USE THEREOF IN GENETIC ANALYSIS
4y 8m to grant Granted Nov 03, 2026
Patent 12774490
CONSTRUCT FOR CONTINUOUS MONITORING OF LIVE CELLS
5y 0m to grant Granted Oct 27, 2026
Patent 12774462
Surface-Based Tagmentation
4y 2m to grant Granted Oct 27, 2026
Patent 12767945
METHODS AND COMPOSITIONS FOR MULTIPLEX GENE EDITING
4y 10m to grant Granted Oct 20, 2026
Patent 12753448
DETECTION AND PREDICTION OF INFECTIOUS DISEASE
5y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+43.8%)
4y 3m (~1y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 61 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month